Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

With two approved drugs and close to 300 clinical / preclinical product candidates<Roots>


With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

 

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

 

The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:

§  Therapeutic Area 

  • Autoimmune Disorders
  • Eye Disorders
  • Genetic Disorders
  • Hematological Malignancies
  • Infectious Diseases
  • Inflammatory Disorders
  • Skin Disorders

 

§  Mechanism of Action

  • Cytokines Retargeting / Neutralization
  • Dual Ligands Blocking
  • T-cell Retargeting / Activation
  • Others

 

§  Target Antigens

  • CD3 x CD19
  • CD30 x CD16A
  • Factor IXa x Factor X
  • IL-1α x IL-1β
  • IL-13 x IL-4
  • IL-17A x Albumin
  • IL-17A x IL-17F
  • Psl x PcrV
  • VEGF-A x ANG2
  • Others

 

§  Antibody Formats

  • Asymmetric
  • Fragments
  • Symmetric
  • Others

 

§  Key Geographical Regions 

  • North America
  • Europe
  • Asia-Pacific

 

The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

§  Amgen

§  Ablynx

§  AbbVie

§  Affibody

§  Affimed

§  Alphamab

§  AstraZeneca

§  Avillion

§  Chugai Pharmaceuticals

§  Eddingpharm

§  GSK

§  Merck

§  Merus

§  Roche

§  Regeneron Pharmaceuticals

§  Taisho Pharmaceuticals

§  Zymeworks

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction
 

4. Market Overview
 

5. Bispecific Antibody Therapeutics: Technology Platforms
 

6. Drug Profiles
 

7. Key Insights 
 

8. Benchmark Analysis: Big Pharma Players
 

9. Partnerships and Collaborations
 

10. Contract Services for Bispecific Antibody Therapeutics
 

11. Clinical Trial Analysis
 

12. Case Study: Regulatory Guidelines for Bispecific Antibodies
 

13. Case Study: Promotional / Marketing Strategies
 

14. SWOT Analysis

 

15. Market Forecast and Opportunity Analysis

 

16. Concluding Remarks

 

17. Executive Insights

 

18. Appendix 1: Tabulated Data

 

19. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

 

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...